Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases

A compound of Formula I

• wherein:
• R1 is CN or Cl;
• R2 is C1-C6 alkoxy, C1-C6 alkyl, C3-C6 cycloalkoxy, or phenyl optionally substituted with 1-2 groups independently selected from halogen and (C3-C6 cycloalkyl) C(═O)NH—;
• Ring A is Ar1 or hetAr1;
• Ar1 is phenyl optionally substituted with 1-2 groups independently selected from halogen, C1-C6 alkyl, fluoroC1-C6 alkyl, and C1-C6 alkoxy;
• hetAr1 is a 5-6 membered heteroaryl ring having 1-3 ring nitrogen atoms and optionally substituted with 1-2 independently selected halogen, C1-C6 alkyl, fluoroC1-C6 alkyl, or C1-C6 alkoxy substituents;
• Ring B is a 4-8 membered monocyclic heterocyclic ring having 1-2 ring nitrogen atoms, a 7-11 membered bridged heterocyclic ring having 1-2 ring nitrogen atoms, a 7-12 membered spiroheterocyclic ring having 2 ring nitrogen atoms, or absent;
• L is —C(═O)—,—CH2—, —SO2—, —C(═O)NH*, or absent, wherein the asterisk indicates the point of attachment to Ring C;
• Ring C is Cyc1, Cyc2, hetCyc1, hetCyc2, hetCyc3, Ar3, or absent;
• Cyc1 is 4-8 membered cycloalkyl ring optionally substituted with halo, CN, OH, C1-C6 alkyl, fluoroC1-C6 alkyl, and C1-C6 alkoxy;
• Cyc2 is a 5-11 membered bridged cycloalkyl ring;
• hetCyc1 is a 4-6 membered heterocyclic ring having 1-2 ring nitrogen atoms and optionally substituted with 1-4 substituents independently selected from halogen, CN, OH, C1-C6 alkyl, C1-C6 alkoxy, and cyanoC1-C6 alkyl;
• hetCyc2 is a 7-11 membered bridged heterocyclic ring having 1-3 ring heteroatoms independently selected from N and O;
• hetCyc3 is a 7-12 membered spiroheterocyclic ring having 1-2 ring nitrogen atoms;
• Ar3 is phenyl optionally substituted with C1-C6 alkyl or C1-C6 alkoxy;
• Y is —NH—, —N(C1-C3 alkyl)-, or absent;
• W is R3R4C═CR5C(═O)—, R6R7NCH2CH═CHC(═O)—, H2C═CHSO2— or R8C═C≡C(═O)—;
• R3 is hydrogen;
• R4 is hydrogen, CF3 or Z (C1-C6 alkyl)-wherein Z is H, F, Cl, Br, HO—, or C1-C6 alkoxy, and
• R5 is hydrogen, C1-C3 alkyl, or halogen,
• or R4 and R5 together with the carbon atoms to which they are attached form a 4-8-membered carbocyclic ring;
• each of R6 and R7 is independently C1-C6 alkyl, or R6 and R7 together with the nitrogen atom to which they are attached form a 5-6 membered heterocyclic ring optionally having an additional ring heteroatom which is O, wherein said ring is optionally substituted with halogen;
• R8 is hydrogen, C1-C3 alkyl, HO-C1-C3 alkyl or R′R″NCH2—;
• and
• R′ and R″ are each independently hydrogen or C1-C6 alkyl,
• or a pharmaceutically acceptable salt thereof.